Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva CEO Calls 'Trough' Revenues Consequence of Patent Expirations - YouTube
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - BNN Bloomberg
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Drugmaker Teva makes $40B bid for rival Mylan
Teva plans to raise Mylan bid by as much as $2 billion: Bloomberg | Reuters
Teva makes $40B offer for Mylan
Teva Considering Cutting up to 10,000 Jobs: Bloomberg
Teva's $4 Billion Medicine Faces Patent Judgment Day in U.S. - Bloomberg
Teva Loses CEO, Leaving Investors to Guess What's Next - Bloomberg
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Tags search | Ctech
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
A bottle of Teva Pharmaceutical Industries Ltd. Clonazepam medication... News Photo - Getty Images
Actavis CEO: Teva-Mylan deal could be "value-destroying" - גלובס
The Difficulties of Cloning a CEO - Bloomberg
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva's Credit Rating Cut to Junk by Fitch - Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva looks to sell generics in China through joint venture with Guangzhou Pharma: Bloomberg | Fierce Pharma
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva (TEVA) Agrees to $225 Million Texas Opioid Settlement, AG Says - Bloomberg
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
